The selective ablation of inflammation in an acute stage of ischemic stroke may be a new strategy to promote neurogenesis.

Ischemic stroke is one of the most common diseases in the world. Pre-clinical studies have proved that stem cell therapy is effective in treating ischemic stroke. But there is a "time window" for stem cell therapy that is only limited in acute/subacute stage after stroke. Meanwhile, ischemic stroke can elicit an immediate neuroinflammatory reaction in the brain, and an uncontrolled inflammatory process in acute/subacute stage will impair survival of stem cells and block repair processes. A selective ablation of harmful inflammation factors can greatly decrease a hostile environment and facilitate neurogenesis. If detrimental factors of inflammation in an acute/subacute stage after an ischemic stroke are suitably handled and more specific immunomodulatory interventions are adopted, neurogenesis in the "time window" will greatly enhanced.